Emerging therapies in multiple myeloma
The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomi...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | article |
| منشور في: |
2015
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6243 http://dx.doi.org/10.1097/COC.0b013e3182a4676b http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.lww.com/amjclinicaloncology/Abstract/2015/06000/Emerging_Therapies_in_Multiple_Myeloma.15.aspx |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513478944882688 |
|---|---|
| author | El-Amm, Joelle |
| author2 | Tabbara, Imad A. |
| author2_role | author |
| author_facet | El-Amm, Joelle Tabbara, Imad A. |
| author_role | author |
| dc.creator.none.fl_str_mv | El-Amm, Joelle Tabbara, Imad A. |
| dc.date.none.fl_str_mv | 2015 2017-09-22T12:20:35Z 2017-09-22T12:20:35Z 2017-09-22 |
| dc.identifier.none.fl_str_mv | 1537-453X http://hdl.handle.net/10725/6243 http://dx.doi.org/10.1097/COC.0b013e3182a4676b El-Amm, J., & Tabbara, I. A. (2015). Emerging therapies in multiple myeloma. American journal of clinical oncology, 38(3), 315-321. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.lww.com/amjclinicaloncology/Abstract/2015/06000/Emerging_Therapies_in_Multiple_Myeloma.15.aspx |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | American Journal of Clinical Oncology |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Emerging therapies in multiple myeloma |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib). The median overall survival of multiple myeloma patients has increased significantly with patients younger than age 50 years experiencing a 10-year survival rate of around 40%. However, despite the increased effectiveness of the first-line agents, the majority of patients will eventually relapse and become drug resistant. Promising novel therapies have recently emerged and are being used to treat relapsed and refractory patients. This review will cover the clinical data regarding these emergent therapies that include new generation of proteasome inhibitors (carfilzomib, ixazomib, oprozomib, and marizomib), immunomodulatory drugs (pomalidomide), monoclonal antibodies (elotuzumab and daratumumab), signal transduction modulator (perifosine), and histone deacetylase inhibitors (vorinostat and panobinostat). |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_fbecf3a1d5891bef6024ced6eb8c015b |
| identifier_str_mv | 1537-453X El-Amm, J., & Tabbara, I. A. (2015). Emerging therapies in multiple myeloma. American journal of clinical oncology, 38(3), 315-321. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/6243 |
| publishDate | 2015 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Emerging therapies in multiple myelomaEl-Amm, JoelleTabbara, Imad A.The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib). The median overall survival of multiple myeloma patients has increased significantly with patients younger than age 50 years experiencing a 10-year survival rate of around 40%. However, despite the increased effectiveness of the first-line agents, the majority of patients will eventually relapse and become drug resistant. Promising novel therapies have recently emerged and are being used to treat relapsed and refractory patients. This review will cover the clinical data regarding these emergent therapies that include new generation of proteasome inhibitors (carfilzomib, ixazomib, oprozomib, and marizomib), immunomodulatory drugs (pomalidomide), monoclonal antibodies (elotuzumab and daratumumab), signal transduction modulator (perifosine), and histone deacetylase inhibitors (vorinostat and panobinostat).PublishedN/A2017-09-22T12:20:35Z2017-09-22T12:20:35Z20152017-09-22Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1537-453Xhttp://hdl.handle.net/10725/6243http://dx.doi.org/10.1097/COC.0b013e3182a4676bEl-Amm, J., & Tabbara, I. A. (2015). Emerging therapies in multiple myeloma. American journal of clinical oncology, 38(3), 315-321.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://journals.lww.com/amjclinicaloncology/Abstract/2015/06000/Emerging_Therapies_in_Multiple_Myeloma.15.aspxenAmerican Journal of Clinical Oncologyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/62432021-03-19T10:43:18Z |
| spellingShingle | Emerging therapies in multiple myeloma El-Amm, Joelle |
| status_str | publishedVersion |
| title | Emerging therapies in multiple myeloma |
| title_full | Emerging therapies in multiple myeloma |
| title_fullStr | Emerging therapies in multiple myeloma |
| title_full_unstemmed | Emerging therapies in multiple myeloma |
| title_short | Emerging therapies in multiple myeloma |
| title_sort | Emerging therapies in multiple myeloma |
| url | http://hdl.handle.net/10725/6243 http://dx.doi.org/10.1097/COC.0b013e3182a4676b http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.lww.com/amjclinicaloncology/Abstract/2015/06000/Emerging_Therapies_in_Multiple_Myeloma.15.aspx |